SNNLive caught up with Dr. Daniel Teper,
CEO of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) at the Marcum MicroCap Conference 2015 in New York City, NY.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.
IMMUNE is focused on developing the next generation of monoclonal antibodies to
address significant unmet medical needs in
the treatment of cancer and inflammatory diseases. Our goal is to improve patients’ lives through targeted medicine.